Microneedle Delivery of Amphotericin B Shows Promise for American Cutaneous Leishmaniasis Treatment
Microneedle-based delivery of Amphotericin B significantly reduced lesion growth in mice with American cutaneous leishmaniasis.
Asset / Drug
Drug and asset intelligence for Microneedle with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.